https://origin.rootz.global/api/company/MRK| Name | Type | Description |
|---|---|---|
| Keytruda/Keytruda Qlex | service | Anti-PD-1 therapy (pembrolizumab) approved for numerous oncology indications; Keytruda Qlex is a subcutaneous fixed combination with berahyaluronidase alfa. |
| Gardasil/Gardasil 9 | service | HPV vaccines to help prevent certain cancers and diseases caused by human papillomavirus types. |
| Winrevair | service | Activin signaling inhibitor (sotatercept-csrk) indicated for treatment of adults with pulmonary arterial hypertension. |
| Januvia/Janumet | service | Sitagliptin-based oral medications for the treatment of type 2 diabetes. |
| Bridion | service | Sugammadex medication for reversal of neuromuscular blocking agents used during surgery. |
| Prevymis | service | Letermovir for prophylaxis of cytomegalovirus infection in high-risk transplant recipients. |
| Welireg | service | Belzutifan for treatment of VHL disease-associated tumors, advanced RCC, and pheochromocytoma or paraganglioma. |
| Vaxneuvance | service | Pneumococcal 15-valent conjugate vaccine to help prevent invasive pneumococcal disease. |
| Capvaxive | service | Pneumococcal 21-valent conjugate vaccine for prevention of invasive pneumococcal disease and pneumonia in adults. |
| ProQuad/M-M-R II/Varivax | service | Pediatric vaccines for measles, mumps, rubella, and varicella prevention. |
| Partner | Type | Description |
|---|---|---|
| AstraZeneca | licensing | Alliance revenue from Lynparza (olaparib), a PARP inhibitor for ovarian, breast, pancreatic, and prostate cancers. |
| Eisai | licensing | Alliance revenue from Lenvima (lenvatinib), an oral receptor TKI for thyroid cancer, RCC, HCC, and endometrial carcinoma. |
| Bristol-Myers Squibb | licensing | Alliance revenue from Reblozyl (luspatercept-aamt) for treatment of certain types of anemia. |
View all SEC EDGAR filings: EDGAR Company Page
Structured filing index: /api/company/MRK/filings